Ruti Aga's Six-Year Ban: Fake Prescription in Athletics and China's Half Marathon Race

Ethiopian runner Ruti Aga (32) has been handed a six-year ban by the Athletics Integrity Unit (AIU) after testing positive for methylprednisolone following a half marathon win in China in March. The sanction, backdated to a provisional suspension from 10 September, combines a two-year period for the presence violation and a four-year tampering charge for submitting a forged prescription issued by a family member posing as a doctor. The case reveals a critical intersection of medical governance failure and document fabrication in East African road-running entourages. The source article mislabels methylprednisolone as a "prohibited steroid," but it is a glucocorticoid (WADA Prohibited List class S9), not an anabolic steroid (S1). S9 glucocorticoids are prohibited in-competition only, by injection, oral, or rectal routes. This distinction is decisive: a therapeutic knee injection is legal out-of-competition and becomes a violation only if residues are present during the competition window. The case therefore hinges on route of administration and timing, not on "steroid use." Aga's performance data is absent from the source, making any form assessment impossible. The only performance-relevant fact is that she won a half marathon in China in March, implying a World Athletics Label-tier elite field with in-competition testing. Her career record includes a 2026 Tokyo Marathon title and three World Marathon Major runner-up finishes. At 32, a six-year ban running to roughly age 38 effectively ends her elite career, and Ethiopia's women's marathon depth makes a returnee with a doping record unselectable. The 2 + 4 sanction arithmetic is internally consistent with standard Code sanctions: two years for the presence violation (likely a Specified Substance finding without proven intent) and four years for tampering (the Code's standard tampering sanction). The panel appears to have rejected no-significant-fault mitigation for the presence charge. Backdating to 10 September is a procedural benefit, not a reduction — provisional suspension time counts against the ban. The knee injury cited as the reason for treatment is mechanistically plausible but legally fatal. Intra-articular or peri-articular methylprednisolone for knee synovitis is standard sports-medicine practice in distance runners. That plausibility is precisely why the forgery is the decisive fact: a genuinely documented treatment would have been defended with real records. The "doctor" was a family member with no medical registration who claimed to have used an old prescription pad from a former workplace. This is not a filing error — it is the signature of an athlete operating without a credentialed team physician. No TUE infrastructure appears to have been in place. The competitive landscape is unaffected. A 32-year-old with zero global championship medals leaving the sport changes nothing in Ethiopian selection calculus. Her three Major second places were commercial-tier results, not championship conversions. The more consequential pattern is the clustering of AIU road-running cases involving tampering, suggesting the enforcement frontier has shifted from detection to document verification. Aga's case belongs to a recognizable family of East African road-racing cases where the initial substance violation is compounded by a fabricated or altered explanation. China's label-race circuit is now a high-scrutiny zone. The intersection of large appearance-fee budgets, deep East African elite fields, and AIU testing means results from this tier will increasingly carry integrity risk. The appearance-fee economy and the testing economy are colliding in the same races. Aga's commercial and historical standing is now bifurcated: the 2026 Tokyo title and three Major runner-up finishes remain the record of a genuinely elite marathoner, while the ban makes her commercially radioactive in a sport where distance-running sponsorship is already thin. A six-year ban for a glucocorticoid — a substance with no proven endurance benefit — is a striking outcome that will be cited both as evidence of AIU rigor and as evidence of disproportionate enforcement against African road runners. The tampering charge arises from an interview, i.e., from statements made under questioning, not from a document alone. Language and translation conditions in AIU interviews with Ethiopian athletes are a recurring point of contention. However, the forgery finding is document-based and hard to overturn. A CAS appeal window (typically ~21 days from the reasoned decision) exists, but the likelihood of success is low. The disqualification scope is unstated but almost certainly includes the March race result and its prize money, plus forfeiture of any ranking points accrued after that date. Standard AIU practice is automatic disqualification of the competition where the sample was collected. The case likely began as a whereabouts/passport-adjacent investigation rather than a routine in-competition test, given the interview-based tampering charge. The lesson from Aga's case is that a potentially manageable substance violation can be converted into a career-terminal event by forged documentation and misleading interview statements. With genuine medical records and a correct route/timing explanation, the presence charge could have been argued at the no-fault/no-significant-fault end, potentially resulting in a reprimand or a substantially reduced period, with no tampering charge at all. This case underscores the necessity of medical governance and document verification in athletics.